A century-long story, now entering its industrial age

Figure 1. The peptide drug journey: from insulin to GLP-1 and greener process chemistry.

Peptide therapeutics are no longer a specialized corner of pharmaceutical innovation. They have moved from a historically important but relatively niche modality into one of the most strategically important areas in modern drug development. From insulin to 

GLP-1 receptor agonists, from metabolic disease to oncology and rare diseases, peptides are now redefining what is possible between small molecules and biologics.

The story began more than a century ago with insulin. As one of the earliest and most impactful peptide medicines, insulin changed diabetes from a fatal diagnosis into a manageable chronic condition. For decades, peptide drugs were mainly associated with hormone replacement, endocrine disorders, and injectable therapies. Their advantages were clear: high potency, strong target specificity, and biological relevance. Their limitations were also clear: short half-life, enzymatic degradation, poor oral bioavailability, and complex manufacturing.

The second major turning point came with chemistry. Solid-phase peptide synthesis, introduced by R. Bruce Merrifield, gave scientists a practical platform to build peptide chains step by step on a polymer support. Merrifield later received the 1984 Nobel Prize in Chemistry for the development of methodology for chemical synthesis on a solid matrix. Later advances in recombinant DNA technology, purification, analytical chemistry, and formulation science further expanded the peptide drug toolbox. Today, the field is entering a new phase: peptides are not only discovered; they are engineered.

GLP-1 made peptides a supply-chain priority

That evolution is visible in the current GLP-1 wave. Semaglutide, tirzepatide, and next-generation incretin-based therapies have transformed the treatment landscape for type 2 diabetes and obesity. Recent reviews describe GLP-1-based therapies as highly effective options that can improve glycemic control, support weight loss, and reduce cardiovascular and renal risks in selected patient populations. The pipeline is also moving beyond single GLP-1 receptor agonism toward dual and triple agonists, oral approaches, long-acting molecules, peptide conjugates, and more sophisticated delivery strategies.

For the pharmaceutical supply chain, this success creates a new question: can peptide manufacturing scale fast enough, cleanly enough, and reliably enough? The answer depends not only on large reactors and headline capacity announcements. It also depends on the quality and sustainability of the chemistry underneath.

Modern peptide manufacturing is a highly integrated process involving protected amino acids, resins, coupling reagents, solvents, bases, scavengers, purification systems, analytical control, and regulatory documentation. In this value chain, some raw materials may not appear in the final active pharmaceutical ingredient, but they strongly influence yield, purity, impurity profiles, cost, waste, and process robustness.

Figure 2. Piperidine in the repeated Fmoc-SPPS deprotection cycle.

Bio-based Piperidine: a quiet but process-critical reagent

One of the most important materials in Fmoc-SPPS is piperidine. In this chemistry, Fmoc protects the alpha-amino group of amino acids during chain build-up. After each coupling step, the Fmoc group must be removed efficiently before the next amino acid can be added. Piperidine, commonly used in polar aprotic solvents such as DMF or NMP, performs this deprotection step and helps trap the reactive dibenzofulvene intermediate formed during the reaction.

This may sound like routine chemistry. In practice, it is mission-critical. A peptide chain may require dozens of repeated deprotection and coupling cycles. If one deprotection step is incomplete, the next coupling step may fail at that position, generating deletion sequences and related impurities. These impurities can be structurally close to the target peptide, making downstream purification more difficult and reducing overall yield.

That is why piperidine is more than a commodity base in peptide manufacturing. It is a process-enabling reagent. Its performance affects deprotection kinetics, impurity formation, resin-bound peptide integrity, and the reproducibility of the SPPS cycle. Process chemists must consider piperidine concentration, exposure time, solvent system, resin loading, peptide sequence, aggregation behavior, temperature, washing efficiency, and residual base control.

Sustainability is moving upstream

At the same time, the peptide industry is facing a sustainability challenge. Fmoc-SPPS is powerful and flexible, but it is also resource-intensive. Large volumes of solvents and repeated washing cycles contribute to high process mass intensity. Reviews of greener SPPS emphasize that traditional polar aprotic solvents such as DMF, NMP, and DMAc, as well as chlorinated solvents such as DCM, have long been widely used in peptide synthesis, while industry and academia continue to search for safer and more sustainable alternatives.

This is where bio-based piperidine becomes strategically relevant. A more sustainable peptide supply chain does not have to begin with a complete redesign of the synthesis route. In many cases, it begins with replacing fossil-derived inputs with technically equivalent, traceable, renewable-carbon alternatives. Piperidine is traditionally associated with fossil-based routes, including hydrogenation of pyridine. Biobased piperdine doesn’t only offer an alternative carbon source,but strengthen the supply chain resilience since it is not depending on petroleum oil.

For peptide manufacturers, a bio-based piperidine can support a lower-fossil-carbon raw material strategy without forcing customers to abandon familiar Fmoc-SPPS chemistry. In regulated pharmaceutical manufacturing, changing a core reagent is never trivial. A drop-in or near drop-in raw material with comparable technical specifications can be more practical than a disruptive process change.

Figure 3. Bio-based piperidine as a practical upstream sustainability lever.

Our bio-based piperidine: performance with a sustainability lens

This is the value proposition behind our bio-based piperidine. It is designed for customers who need both performance and responsibility: the deprotection efficiency expected in Fmoc-SPPS, the consistency required for demanding chemical processes, and the renewable-carbon positioning increasingly valued by pharmaceutical and CDMO procurement teams.

The advantage is practical rather than rhetorical. For peptide API manufacturers, bio-based piperidine can help align process chemistry with the next generation of pharmaceutical sustainability expectations. It also gives procurement and technical teams a more credible story: sustainability supported by raw material traceability, specification control, and supplier documentation, not just by a general environmental claim.

In practice, Biobased piperidine not only offers affordable sustainable choice, but with comparably good specification which is favored by pharmaceutical grade peptides producers.

Specification: